XRTX
XORTX Therapeutics Inc. NASDAQ Listed Sep 23, 2021$2.65
Pre-mkt
$2.41
-0.75%
Mkt Cap $737,996
52w Low $1.73
17.4% of range
52w High $7.05
50d MA $2.31
200d MA $3.11
P/E (TTM)
-0.1x
EV/EBITDA
0.1x
P/B
0.2x
Debt/Equity
0.0x
ROE
—
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
0.09
50d MA
$2.31
200d MA
$3.11
Avg Volume
1.3M
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
421 – 7th Avenue SW · Vancouver, BC T2P 4K9 · CA
Data updated apr 27, 2026 10:54am
· Source: massive.com